NRx Pharmaceuticals, Inc.
NRXP
$3.28
$0.072.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 306.20% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 306.20% | -- | |||
| Cost of Revenue | 320.62% | -- | |||
| Gross Profit | 296.55% | -- | |||
| SG&A Expenses | 62.71% | 2.37% | |||
| Depreciation & Amortization | 61.54% | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.91% | 16.89% | |||
| Operating Income | -11.56% | -10.40% | |||
| Income Before Tax | 106.11% | 66.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 106.11% | 66.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 106.11% | 66.50% | |||
| EBIT | -11.56% | -10.40% | |||
| EBITDA | -10.79% | -10.19% | |||
| EPS Basic | 104.68% | 72.98% | |||
| Normalized Basic EPS | 37.14% | 69.91% | |||
| EPS Diluted | 104.68% | 72.98% | |||
| Normalized Diluted EPS | 37.14% | 69.91% | |||
| Average Basic Shares Outstanding | 30.27% | 23.96% | |||
| Average Diluted Shares Outstanding | 30.27% | 23.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||